Human Papillomavirus Vaccine (HPV) Market to Reach US$ 7.71 Billion by 2034
Human Papillomavirus (HPV) vaccines are preventive biologics designed to protect against high-risk HPV strains responsible for most cervical and several other cancers. These vaccines represent one of the most impactful cancer prevention tools in modern public health by reducing infection rates before disease onset. Continuous improvements in multivalent formulations are expanding protection...